The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1288
Addendum: Warfarin-Acetaminophen Interaction
Download PDF:   US English
Med Lett Drugs Ther. 2008 Jun 16;50(1288):45
Disclosures
Objective(s)
 Select a term to see related articles  2008   5FU   addendum   Adrucil   Amiodarone   Anticoagulants   Bactrim   Barbiturates   Carafate   Carbamazepine   Cholestyramine   Colestid   Colestipol   Cordarone   Coumadin   Coumarin   Crestor   CYP2C9   Diflucan   Dilantin   drug interactions   Flagyl   Fluconazole   Fluorouracil   fluoxetine   Fluvastatin   Fluvoxamine   genetic tests   Genotype   Issue 1288   June 16   Lescol   Luvox   metronidazole   page 45   Pharmacogenetic-Based Dosing of Warfarin   Phenytoin   Polymorphisms   Prozac   Questran   Rifadin   Rifampin   Rosuvastatin   St. John's wort   Sucralfate   Sulcrate   Tegretol   Trimethoprim-sulfamethoxazole   Vfend   Vitamin K   VKORC1   volume 50   Voriconazole   Warfarin   Warfarin-Acetaminophen Interaction 

A reader expressed disappointment that our recent listing of “Some Warfarin Drug Interactions”1 did not include acetaminophen. Perhaps it should have. Acetaminophen can increase the anticoagulant effect of warfarin, particularly with continued use, but it does so inconsistently. The mechanism of this interaction has not been established, but may be related to an acetaminophen metabolite inhibiting vitamin K-epoxide reductase, the target for warfarin’s anticoagulant effect.2

Patient susceptibility varies, possibly on a genetic basis; occasional use of acetaminophen generally has little or no effect on the international normalized ratio (INR) in patients on chronic warfarin therapy, but in some, even a few grams of the drug may cause a dramatic increase in INR. One study in healthy subjects found no effect of acetaminophen 4 g per day for 2 weeks, while another study in patients with the same acetaminophen dose for the same period of time found a moderate increase in INR.3,4 It might be prudent to monitor INR in patients on chronic warfarin therapy more closely than usual when they take more than 2 g per day of acetaminophen for more than a few days.

1. Pharmacogenetic-based dosing of warfarin. Med Lett Drugs Ther 2008; 50:39.

2. HH Thijssen et al. Paracetamol (acetaminophen) warfarin interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle. Thromb Haemost 2004; 92:797.

3. D Kwan et al. The effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1999; 39:68.

4. I Mahe et al. Paracetamol: A haemorrhagic risk factor in patients on warfarin. Br J Clin Pharmacol 2005; 59:371.

© The Medical Letter, Inc. All Rights Reserved.
This article has been freely provided.
arrow to previous article
arrow to next article